Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$468.63 USD

468.63
827,133

-9.21 (-1.93%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $468.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Zacks.com featured highlights include Lululemon Athletica, Sanderson Farms, IDEXX Laboratories and NVR

Zacks.com featured highlights include Lululemon Athletica, Sanderson Farms, IDEXX Laboratories and NVR

    Cooper Companies Buys Teva's PARAGARD Intrauterine Platform

    Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.

      Ecolab (ECL) Features in DJSI List for Third Consecutive Year

      Ecolab???s (ECL) nomination as a leading player in the Dow Jones Sustainability Index will lend the company a leading position in the healthcare domain.

        Tirthankar Chakraborty headshot

        Buy These 4 Efficient Stocks for Healthy Returns

        Companies with favorable efficiency levels are poised to be on investors' radar irrespective of market conditions

          5 Top-Ranked MedTech Growth Stocks for Solid Returns

          Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.

            Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales

            Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.

              Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?

              Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.

                Cooper to Benefit From Specialty Lenses Prospects Amid Woes

                The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.

                  Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                  The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

                    Align Technology at 52-Week High: What's Driving the Stock?

                    Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

                      Buy These 5 Large Caps on Extraordinary ROI Potential

                      Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.

                        Boston Scientific Grows on Innovation, Buyouts Amid Woes

                        While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

                          HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

                          HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.

                            Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN

                            The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.

                              Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness

                              Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.

                                Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife

                                Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.

                                  Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level

                                  With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.

                                    Hologic (HOLX) Launches Brevera, Progresses in Breast Health

                                    Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.

                                      4 Large-Cap Medical Device Stocks to Buy Amid Political Woes

                                      Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.

                                        Mazor Robotics Hits 52-Week High Through Medtronic Alliance

                                        Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.

                                          GNC Holdings Gains on New GNC Strength Amid Soft Revenues

                                          GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.

                                            3 MedTech Stocks Set to Rally in the Second Half

                                            The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.

                                              Haemonetics Grows on Strong Plasma, Blood Center Sluggish

                                              Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.

                                                Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

                                                Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

                                                  The Cooper Companies (COO) Beats Earnings Estimates in Q3

                                                  The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.